National Cancer Institute / Memorial Sloan-Kettering Cancer Center / Correspondence *Biometric Research Branch National Cancer Institute / /
IndustryTerm
treatment protocols / Cancer Treat / treatment of node-positive primary breast cancer / phenomenological law / /
MedicalCondition
Intergroup trial C9741/Cancer / node-positive primary breast cancer / tumor / cancer / tumors / bacterial infections / primary breast cancer / disease / II breast cancer / early breast cancer / experimental solid tumor / human cancers / pain / operable breast cancer / experimental leukemia / human and experimental solid tumors / breast cancer / unperturbed tumor / easily managed anemia / /
National Cancer Institute / American Association of Cancer Research / Memorial Sloan-Kettering Cancer Center / Memorial Hospital / Medical / Evelyn H. Lauder Breast Center / /
Person
Larry Norton / Norton R Simon / Richard Simon / / /
Position
advocate / Director / Deputy Physicianin-Chief / Chief / /
Product
paclitaxel / cyclophosphamide / fluorouracil / /
ProvinceOrState
New York / /
PublishedMedium
Cancer Research / NATURE CLINICAL PRACTICE ONCOLOGY / /
VIEWPOINT www.nature.com/clinicalpractice/onc The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens